美股异动 | 生物技术公司Fibro Biologics(FBLG.US)上市首日暴涨264% 盘前续涨近40%

智通财经网02-01

智通财经APP获悉，Fibro Biologics(FBLG.US)于周三在纳斯达克直接上市，上市前参考价定为8美元，股票代码为FBLG。纳斯达克参考价并不反映Fibro Biologics股票的发行价或开盘价，开盘价根据纳斯达克开盘竞价中的买卖订单确定。该股上市首日暴涨263.75%，报29.1美元。截至发稿，该股盘前继续上涨37.9%，报43.1美元。据悉，Fibro Biologics于...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2408633450?lang=zh_CN&edition=full","thumbnail":"https://img.zhitongcaijing.com/image/20240201/20240201214242_38372.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","is_english":false,"pubTime":"2024-02-01 21:46","share_image_url":"https://static.laohu8.com/6ca2dcdccfa2217fb20a0351f4efe814","id":"2408633450","market":"us","top_or_hot":-1,"title":"美股异动 | 生物技术公司Fibro Biologics(FBLG.US)上市首日暴涨264% 盘前续涨近40%","media":"智通财经网","content":"<div>\n<p>智通财经APP获悉，Fibro  Biologics(FBLG.US)于周三在纳斯达克直接上市，上市前参考价定为8美元，股票代码为FBLG。纳斯达克参考价并不反映Fibro  Biologics股票的发行价或开盘价，开盘价根据纳斯达克开盘竞价中的买卖订单确定。该股上市首日暴涨263.75%，报29.1美元。截至发稿，该股盘前继续上涨37.9%，报43.1美元。据悉，Fibro Biologics于...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1067089.html\">网页链接</a>\n\n</div>\n","source":"highlight_zhitongcaijin","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>美股异动 | 生物技术公司Fibro Biologics(FBLG.US)上市首日暴涨264% 盘前续涨近40%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n美股异动 | 生物技术公司Fibro Biologics(FBLG.US)上市首日暴涨264% 盘前续涨近40%\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-02-01 21:46 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1067089.html><strong>智通财经网</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP获悉，Fibro  Biologics(FBLG.US)于周三在纳斯达克直接上市，上市前参考价定为8美元，股票代码为FBLG。纳斯达克参考价并不反映Fibro  Biologics股票的发行价或开盘价，开盘价根据纳斯达克开盘竞价中的买卖订单确定。该股上市首日暴涨263.75%，报29.1美元。截至发稿，该股盘前继续上涨37.9%，报43.1美元。据悉，Fibro Biologics于...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1067089.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"FBLG","symbol_name":"FibroBiologics","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1067089.html","article_id":"2408633450","we_media_id":null,"thumbnails":["https://img.zhitongcaijing.com/image/20240201/20240201214242_38372.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2408633450","pubTimestamp":1706795173,"sourceInfo":{"source_id":"highlight_zhitongcaijin","name":"智通财经网"},"weMediaInfo":null,"summary":"Fibro Biologics(FBLG.US)于周三在纳斯达克直接上市，上市首日暴涨263.75%，报29.1美元。截至发稿，该股盘前继续上涨37.9%，报43.1美元。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"FBLG":"FibroBiologics"},"translate_title":"US stocks changed biotechnology company Fibro Biology (FBLG.US) soared 264% on the first day of listing and continued to rise nearly 40% before the market","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"FBLG":1},"content_text":"智通财经APP获悉，Fibro  Biologics(FBLG.US)于周三在纳斯达克直接上市，上市前参考价定为8美元，股票代码为FBLG。纳斯达克参考价并不反映Fibro  Biologics股票的发行价或开盘价，开盘价根据纳斯达克开盘竞价中的买卖订单确定。该股上市首日暴涨263.75%，报29.1美元。截至发稿，该股盘前继续上涨37.9%，报43.1美元。据悉，Fibro Biologics于2021年从原母公司Fibro  Genesis分拆而出，专注于开发以成纤维细胞为基础的疗法，用于大量医疗需求尚未得到满足治疗慢性病患者，此类需求包括椎间盘退行性病变、多发性硬化症(MS)、伤口愈合和某些癌症。公司最先进的候选产品为治疗椎间盘退行性疾病的异体成纤维细胞疗法CybroCell和治疗多发性硬化症的异体成纤维细胞疗法CYMS101。Fibro  Biologics已获得美国FDA的IND许可，可进行CybroCell治疗椎间盘退行性病变的1/2期研究，条件是其主细胞库获得批准。该公司完成了CYMS101在墨西哥对多发性硬化症的1期研究，预计将提交2期试验的IND申请。此次交易没有承销商，Maxim Group LLC将担任公司的财务顾问。","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.25.1","shortVersion":"4.25.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2408633450"}